Can anyone think of other examples where there has been a similar split with the drug developer retaining primary care and licensing out the specialty segment (here pain/neurologists)?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.